Outcomes

Yale Cancer Center and our partner, Smilow Cancer Hospital at Yale-New Haven, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers.  The latest performance data for breast center is listed below.

1. Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with T1c N0 M0, or sate II or III ERA and/or PRA positive breast cancer.
2. Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
3. Combination chemotherapy is considered or administered within 4 months of diagnosis for women under age 70 with T1c N0 M0, or stafe II or III ERA and PRA negative breast cancer.